Pipeline — registered trials by phase
No registered trials in this stage.
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants
— · Healthy Volunteers · Completed · est. 2019-08-01
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
— · Healthy Volunteers · Completed · est. 2015-12-18
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
— · Healthy Participants · Completed · est. 2024-05-24
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
— · Healthy Volunteers · Completed · est. 2023-07-16
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
— · Hepatic Impairment · Completed · est. 2023-06-01
A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
— · Healthy Volunteers · Not Yet Recruiting · est. 2026-11-25
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
— · Healthy Volunteers · Completed · est. 2023-09-22
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
— · Healthy Volunteers · Completed · est. 2025-10-25
A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
— · Healthy Volunteer · Completed · est. 2022-10-07
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
— · Healthy Volunteers · Completed · est. 2024-01-04
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants
— · Healthy Volunteers · Recruiting · est. 2027-03-22
A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants
— · Healthy Volunteers · Completed · est. 2004-06-29
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
— · Amyotrophic Lateral Sclerosis · Recruiting · est. 2030-03-31
A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
— · Healthy Volunteers · Completed · est. 2021-09-14
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
— · Hepatic Impairment · Recruiting · est. 2027-02-07
Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
— · Cystic Fibrosis · Completed · est. 2005-02-08
A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment
— · Renal Impairment · Completed · est. 2023-02-14
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
— · Duchenne Muscular Dystrophy · Active Not Recruiting · est. 2028-01-31
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
— · Healthy Volunteers · Completed · est. 2021-01-12
Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
— · Cystic Fibrosis · Completed · est. 2010-11-02
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
— · Myotonic Dystrophy Type 1 · Completed · est. 2008-12-29
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
— · Bronchiectasis · Completed · est. 2009-05-11
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
— · Mycobacterium Infections, Nontuberculous · Completed · est. 2014-08-18
Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
— · Cystic Fibrosis · Completed · est. 2009-06
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
— · Pulmonary Hypertension · Completed · est. 2024-03-14
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
— · Atopic Dermatitis · Completed · est. 2024-09-03
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
— · Non-Cystic Fibrosis Bronchiectasis · Completed · est. 2019-12-12
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
— · Chronic Rhinosinusitis Without Nasal Polyps · Completed · est. 2025-09-30
Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
— · Cystic Fibrosis · Completed · est. 2008-02-27
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
— · Osteosarcoma Metastatic · Completed · est. 2008-03
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
— · Cystic Fibrosis · Completed · est. 2022-11-01
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
— · Pulmonary Arterial Hypertension · Completed · est. 2025-03-27
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
— · Non-Cystic Fibrosis Bronchiectasis · Completed · est. 2024-10-28
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
— · Mycobacterium Infections, Nontuberculous · Completed · est. 2023-05-09
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
— · Pulmonary Hypertension, Interstitial Lung Disease · Recruiting · est. 2028-12-30
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
— · Pulmonary Arterial Hypertension · Recruiting · est. 2028-12-28
Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
— · Mycobacterium Infections, Nontuberculous · Completed · est. 2018-07-03
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
— · Pseudomonas Aeruginosa Infection · Completed · est. 2013-06
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
— · Cystic Fibrosis · Completed · est. 2015-07-16
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
— · Pulmonary Hypertension, Interstitial Lung Disease · Completed · est. 2026-04-01
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
— · Mycobacterium Infections, Nontuberculous · Completed · est. 2025-11-21
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
— · Progressive Pulmonary Fibrosis, Interstitial Lung Disease · Not Yet Recruiting · est. 2030-08-31
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
— · Pulmonary Arterial Hypertension · Active Not Recruiting · est. 2026-12-31
IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
— · Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome · Completed
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
— · Pulmonary Hypertension, Interstitial Lung Disease · Recruiting · est. 2031-01-22
Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
— · NTM Lung Infection Due to MAC · Completed · est. 2018-10-17
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Insmed is lead sponsor; 46 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-10-05Current report (material event)
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
- 8-K2026-08-06Current report (material event)
- 10-Q2026-08-06Quarterly report
- SCHEDULE 13G/A2026-07-22SCHEDULE 13G/A
- 8-K2026-07-16Current report (material event)
- S-3ASR2026-05-15S-3ASR
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- 8-K2026-05-15Current report (material event)
- 8-K2026-05-07Current report (material event)
- 10-Q2026-05-07Quarterly report
- SCHEDULE 13G2026-05-06SCHEDULE 13G
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- 8-K2026-04-07Current report (material event)
- ARS2026-04-01Annual report to holders
- DEFA14A2026-04-01DEFA14A
- DEF 14A2026-04-01Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-23Current report (material event)
- 10-K2026-02-19Annual report
- 8-K2026-02-19Current report (material event)
- SCHEDULE 13G/A2026-01-21SCHEDULE 13G/A
- 8-K2026-01-09Current report (material event)
- 8-K2025-12-17Current report (material event)
- 8-K2025-11-18Current report (material event)
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- 10-Q2025-10-30Quarterly report
- 8-K2025-10-30Current report (material event)
- SCHEDULE 13G/A2025-09-04SCHEDULE 13G/A
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- 8-K2025-08-12Current report (material event)
- 8-K2025-08-07Current report (material event)
- 10-Q2025-08-07Quarterly report
- SCHEDULE 13G2025-07-30SCHEDULE 13G
- SCHEDULE 13G/A2025-07-17SCHEDULE 13G/A
- 8-K2025-06-13Current report (material event)
- 424B52025-06-12Prospectus (offering)
- 424B52025-06-11Prospectus (offering)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.